Breaking news

Kailera’s Bold Bet: Skipping The Lab, Racing To Market With China’s Ozempic Rivals

While Big Pharma pours billions into obesity drug R&D, a new biotech startup is taking a shortcut: licensing ready-to-go therapies from China. Kailera Therapeutics, launched with $400 million from Bain Capital, Atlas Venture, and RTW Investments, is fast-tracking four obesity drugs developed by Jiangsu Hengrui — one of China’s pharmaceutical heavyweights.

The playbook? Bypass years of early-stage research. “We saw next-gen GLP-1 therapies that could leapfrog existing options,” says Dr. Amir Zamani, Bain’s life sciences partner who spearheaded the deal. One injectable candidate from Hengrui showed 59% of patients losing 20 %+ body weight in Phase II trials, with mild side effects. Even more promising: two of the licensed drugs are pills, a potential game-changer in a market currently dominated by injectables.

With global obesity drug sales projected to hit $131 billion by 2028, Kailera aims to move fast. Leading the charge is biotech veteran Ron Renaud, who’s sold three companies for a combined $16 billion. “We likely have the most advanced and diverse weight-loss pipeline outside Big Pharma,” he says. The goal is to bring the first drug to market by 2030 — a rapid timeline thanks to Hengrui’s head start.

China’s rise as a pharmaceutical R&D hub is reshaping the biotech map. Over a third of molecules licensed by Western firms now originate there. U.S. firms have spent $8.1 billion since 2020 licensing Chinese-developed drugs — a stark contrast to just $536 million in the previous five years.

Kailera is betting this east-west fusion can deliver blockbuster results. With 100 million obese adults in the U.S. alone — not to mention global demand — the addressable market is massive. “This isn’t a one-drug race,” Renaud says. “It’s going to take an entire arsenal.”

To prep for launch, Kailera has added top-tier talent: Scott Wasserman, former cardiovascular lead at Amgen, is chief medical officer; Jamie Coleman, who led Zepbound’s commercial rollout at Lilly, now heads marketing.

Whether Kailera becomes the next independent giant or is eventually snapped up by Big Pharma, as Renaud’s previous ventures were, it’s already a standout in the white-hot weight-loss drug race.

Strained Household Finances: Eurostat Data Reveals Persistent Payment Delays Across Europe and in Cyprus

Improved Financial Resilience Amid Ongoing Strains

Over the past decade, Cypriot households have significantly increased their ability to manage debts—not only bank loans but also rent and utility bills. However, recent Eurostat data indicates that Cyprus continues to lag behind the European average when it comes to covering financial obligations on time.

Household Coping Strategies and the Limits of Payment Flexibility

While many families are managing their fixed expenses with relative ease, one in three Cypriots struggles to cover unexpected costs. This delicate balancing act highlights how routine payments such as mortgage installments, rent, and utility bills are met, but precariously so, with little room for unplanned financial shocks.

Breaking Down Payment Delays Across the European Union

Eurostat reports that nearly 9.2% of the EU population experienced delays with their housing loans, rent, utility bills, or installment payments in 2024. The situation is more acute among vulnerable groups: 17.2% of individuals in single-parent households with dependent children and 16.6% in households with two adults managing three or more dependents faced payment delays. In every EU nation, single-parent households exhibited higher delay rates compared to the overall population.

Cyprus in the Crosshairs: High Rates of Financial Delays

Although Cyprus recorded a notable 19.1 percentage point improvement from 2015 to 2024 in delays related to mortgages, rent, and utility bills, the island nation still ranks among the top five countries with the highest delay rates. As of 2024, 12.5% of the Cypriot population had outstanding housing loans or rent and overdue utility bills. In contrast, Greece tops the list with 42.8%, followed by Bulgaria (18.7%), Romania (15.3%), Spain (14.2%), and other EU members. Notably, 19 out of 27 EU countries reported delay rates below 10%, with Czech Republic (3.4%) and Netherlands (3.9%) leading the pack.

Selective Improvements and Emerging Concerns

Between 2015 and 2024, the overall EU population saw a 2.6 percentage point decline in payment delays. Despite this, certain countries experienced increases: Luxembourg (+3.3 percentage points), Spain (+2.5 percentage points), and Germany (+2.0 percentage points) saw a rise in payment delays, reflecting underlying economic pressures that continue to challenge financial stability.

Economic Insecurity and the Unprepared for Emergencies

Another critical indicator explored by Eurostat is the prevalence of economic insecurity—the proportion of the population unable to handle unexpected financial expenses. In 2024, 30% of the EU population reported being unable to cover unforeseen costs, a modest improvement of 1.2 percentage points from 2023 and a significant 7.4 percentage point drop compared to a decade ago. In Cyprus, while 34.8% still report difficulty handling emergencies, this marks a drastic improvement from 2015, when the figure stood at 60.5%.

A Broader EU Perspective

Importantly, no EU country in 2024 had more than half of its population facing economic insecurity—a notable improvement from 2015, when over 50% of the population in nine countries reported such challenges. These figures underscore both progress and persistent vulnerabilities within European households, urging policymakers to consider targeted measures for enhancing financial resilience.

For further insights and detailed analysis, refer to the original reports on Philenews and Housing Loans.

The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter